A study has reported low switch-back rates for patients with inflammatory bowel disease (IBD) switched from the reference infliximab product to Amgen’s biosimilar Avsola (infliximab-axxq), ABP 710 .
Low switch-back for patients treated with Avsola for IBD
Biosimilars/Research | Posted 06/06/2023 0 Post your comment
The study analysed data from electronic health records and insurance claims of patients who were initially switched from the infliximab reference product (Remicade) to ABP 710. The switch-back rates, which refer to patients switching back to the reference product after being switched to the biosimilar, were examined to assess the real-world effectiveness and acceptance of ABP 710.
Infliximab is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α). It is used to treat autoimmune diseases, such as ankylosing spondylitis, Crohn’s disease (CD), psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis (UC) .
ABP 710 is approved for use as treatment for IBD-related, immune-mediated diseases such as CD and UC in number of regions including the US and Canada [3, 4].
The findings of the study indicate that the switch-back rates from ABP 710 to the infliximab reference product were low. During the study follow-up period, 74.5% of switchers and 51.3% of infliximab-naïve patients remained on ABP 710 treatment without a treatment gap. This suggests that patients who switched to the biosimilar were generally satisfied with its efficacy and safety, as well as their overall treatment outcomes. The low switch-back rates also indicate a high level of acceptance and confidence in the biosimilar among patients and healthcare providers.
The study's results align with previous research that has shown comparable clinical effectiveness and safety between biosimilars and their reference products. Biosimilars are highly similar to the reference biologicals in terms of efficacy, safety and quality. Therefore, the findings support the notion that biosimilars can provide a cost-effective alternative for patients with IBD while maintaining similar treatment outcomes.
The study highlights the importance of real-world evidence in assessing the performance and acceptance of biosimilars. Real-world studies provide valuable insights into the use of biosimilars in routine clinical practice and can help guide decision-making for both patients and healthcare providers.
LATIN AMERICAN FORUM
View the latest headline article: Declaración conjunta sobre biosimilares en enfermedades inmunomediadas en España
Browse the news in the Latin American Forum!
Ver el último artículo de cabecera: Declaración conjunta sobre biosimilares en enfermedades inmunomediadas en España
!Explore las noticias en el Foro Latinoamericano!
1. JinR, ArvizuM, Harris Collier D, Melmed G, et al. EP146: Treatment Patterns Of An Infliximab Biosimilar (Abp 710) Among Patients With Inflammatory Bowel Disease (Ibd): A Retrospective Us Claims Database Analysis. Abstract presented at Digestive Disease Week (DDW) 2023 Annual Meeting. Chicago, IL. May 6-10, 2023.
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of infliximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jun 6]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-infliximab
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jun 6]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-the-us
4. GaBI Online - Generics and Biosimilars Initiative. Canada approves infliximab and filgrastim biosimilars Avsola and Nivestym [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jun 6]. Available from: www.gabionline.net/biosimilars/news/Canada-approves-infliximab-and-filgrastim-biosimilars-Avsola-and-Nivestym
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.